bcbs glp-1 coverage Drugs: What Employers Need to Know Blue Cross Blue Shield of

doi: 10.2337/dci23-0048

The most common side effects are gastrointestinal nausea, diarrhea, constipation which often improve over time

and treatment, thereby advancing the progress of precision medicine

The substantial weight loss achieved with GLP-1 receptor agonists and dual GIP/GLP-1 agonistsapproximately 15% with semaglutide 2.4 mg (Wegovy) and up to 21% with higher doses of tirzepatide (Zepbound) in clinical trialsoccurs primarily through appetite suppression and reduced caloric intake rather than increased metabolic rate

Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD Randomized Clinical Trial

This data underscores how Ozempic and other semaglutide drugs can cause real harms to patients